2 3


Foreword 3

Part 1. Key messages 4

Part 2. Introduction 5

Part 3. Global pharmacy workforce description 8

Part 4. Pharmacy education 19

Part 5. Pharmacy workforce planning, management and development - case studies 29

5.1 Afghanistan

5.2 Costa Rica

5.3 Ghana

5.4 Great Britain

5.5 Japan

5.6 Pacific Islands

5.7 Singapore

5.8 South Africa

5.9 Tanzania

Part 6. Strengthening the pharmacy workforce through transforming and scaling up education 72

Part 7. Summary 76

Annex 1. Data table 77

Annex 2. Acknowledgements 81


On the occasion of the International Pharmaceutical Federation s 100th anniversary, a number ofcrucial initiatives are taking place towards advancing pharmacy practice, science and education, including holding a Ministers Summit on the Added Value of the Responsible Use of Medicines. In recognition of our past 100 years of achievement, this 2012 Global Pharmacy Workforce Report serves as an important reminder of the efforts that national professional and scientific associations, governments and academic institutions have made - and continue to make - to prepare a competent pharmacy workforce that adds value to health care systems through ensuring the responsible use of medicines.

Findings from this report clearly show that professional associations are important stakeholders in advancing the pharmacy workforce. Collaboration between Ministries of Health, Ministries of Education, educational institutions and professional associations pave the way to better plan and coordinate a pharmacy workforce that can respond to the current and future needs of the local population. Political will and investment are crucial aspects to secure pharmacy human resource capacity building. If the pharmacy workforce is to add value through responsible medicines use, the workforce must be present in sufficient numbers and with the competencies required to fulfil the needs of the local population.

We hope that this report will serve as a valuable evidence based instrument to stimulate further research, discussion and policy action.

This report was only possible with the support of over 120 contributors across 90 countries and territories from pharmacy professional and regulatory bodies, schools of pharmacy, research centres, agencies, and pharmaceutical service providers who generously gave their time to obtain data and share their experiences. Thank you also to members of the Report Working Group, FIP volunteers and World Health Organization staff, for their leadership, close collaboration and extensive input to make this report a reality. On behalf of FIP, I would like to express our sincere appreciation of the efforts made by all contributors.

Michel Buchmann, PhD President International Pharmaceutical Federation (FIP)